[1] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
[2] Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2019,104(9):3939-3985.
[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver diseas: an international expert consensus statement. J Hepatol, 2020, 7(1): 202-209.
[4] Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology, 2017, 153(4): 1006-1017.
[5] Huang J, Jing M, Wang C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease:a population-based study. J Med Virol, 2020, 92(8): 1191-1197.
[6] Zhong GC, Wu YL, Hao FB, et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population:a case-control study with propensity score analysis. J Viral Hepat, 2018, 25(7): 842-852.
[7] Yang MH, Sung J, Gwak GY, et al. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol, 2016, 10(2): 289-298.
[8] Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology, 2008, 135(1): 111-121.
[9] Sohn W, Lee HW, Lee S, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol, 2021, 27(1): 157-174.
[10] Nderitu P, Bosco C, Garmo H, et al. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort. Int J Cancer, 2017, 141(6): 1148-1160.
[11] Tan Y, Zhang X, Zhang W, et al. The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis b infection in Mainland China. Cancer Epidemiol Biomarkers Prev, 2019, 28(12): 2038-2046.
[12] Tung HD, Wang JH, Tseng PL, et al. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol, 2010, 105(3): 624-631.
[13] Coman LI, Coman OA, B?d?r?u IA, et al. Association between liver cirrhosis and diabetes mellitus: a review on hepatic outcomes. J Clin Med, 2021, 10(2):262.
[14] Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
[15] Choi HSJ, Brouwer WP, Zanjir WNR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology, 2020, 71(2): 539-548.
[16] Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018, 67(1): 123-133.
[17] Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep, 2021, 3(5): 100350.
[18] Choe JW, Hyun JJ, Kim B, et al. Influence of metabolic syndrome on cancer risk in HBV carriers: a nationwide population based study using the national health insurance service database. J Clin Med, 2021, 10(11):2401.
[19] Kim NH, Cho YK, Kim BI, et al. Effect of metabolic syndrome on the clinical outcomes of chronic hepatitis B patients with nucleos(t)ide analogues treatment. Dig Dis Sci, 2018, 63(10): 2792-2799.
[20] Hsiang JC, Wong GL, Chan HL, et al. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther, 2014, 40(6): 716-726.
[21] Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol, 2019, 70(3): 361-370.
[22] Chettouh H, Lequoy M, Fartoux L, et al. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int, 2015, 35(10): 2203-2217.
[23] Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab, 2016, 27(2): 84-95.
[24] Goh MJ, Sinn DH, Kim S, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology, 2020, 71(6): 2023-2032.
[25] Jarcuska P, Drazilova S, Fedacko J, et al. Association between hepatitis B and metabolic syndrome: current state of the art. World J Gastroenterol, 2016, 22(1): 155-164.
[26] Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology, 2010, 138(5): 1747-1754.
[27] Auth PA, da Silva GR, Amaral EC, et al. Croton urucurana Baill. Ameliorates metabolic associated fatty liver disease in rats. Front Pharmacol, 2022, 13: 886122.
[28] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol, 2019, 71(4): 793-801. |
